TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. By Cancer History Project May 7, 2004
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. By Cancer History Project May 7, 2004
TCL Archive Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work. By Cancer History Project May 7, 2004
TCL Archive Michelle Le Beau named director of University of Chicago Cancer Research Center. By Cancer History Project May 7, 2004
TCL Archive Research teams link response to Iressa to mutations in EGF receptor. By Cancer History Project April 30, 2004
TCL Archive Diet and Cancer Risk Explored In Studies Presented At AACR Annual Meeting By Cancer History Project April 30, 2004
Article Fran Visco tells the story of NBCC: “Women have declared war on breast cancer” By Cancer History Project
